Lipocine Inc
LPCN4.250USD
+0.050+1.19%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
23.04MMarket Cap
LossP/E TTM
More Details of Lipocine Inc Company
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
Lipocine Inc Info
Ticker SymbolLPCN
Company nameLipocine Inc
IPO dateMar 21, 2014
CEOPatel (Mahesh V)
Number of employees16
Security typeOrdinary Share
Fiscal year-endMar 21
Address675 S Arapeen Dr Ste 202
CitySALT LAKE CITY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code84108-1295
Phone18019947383
Websitehttps://www.lipocine.com/
Ticker SymbolLPCN
IPO dateMar 21, 2014
CEOPatel (Mahesh V)
Company Executives of Lipocine Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Mahesh V. Patel, Ph.D.
Dr. Mahesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
109.05K
+1.52%
Mr. John W. Higuchi
Mr. John W. Higuchi
Director
Director
40.80K
--
Dr. Nachiappan Chidambaram, Ph.D.
Dr. Nachiappan Chidambaram, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
4.41K
+11.54%
Ms. Krista Fogarty
Ms. Krista Fogarty
Principal Accounting Officer, Corporate Controller
Principal Accounting Officer, Corporate Controller
1.07K
+44.84%
Dr. Richard Dana Ono, Ph.D.
Dr. Richard Dana Ono, Ph.D.
Independent Director
Independent Director
831.00
--
Mr. Jeffrey A. (Jeff) Fink
Mr. Jeffrey A. (Jeff) Fink
Independent Director
Independent Director
386.00
--
Dr. Jill M. Jene, Ph.D.
Dr. Jill M. Jene, Ph.D.
Independent Director
Independent Director
--
--
Mr. Spyros Papapetropoulos, M.D., Ph.D.
Mr. Spyros Papapetropoulos, M.D., Ph.D.
Lead Independent Chairman of the Board
Lead Independent Chairman of the Board
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Mahesh V. Patel, Ph.D.
Dr. Mahesh V. Patel, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
109.05K
+1.52%
Mr. John W. Higuchi
Mr. John W. Higuchi
Director
Director
40.80K
--
Dr. Nachiappan Chidambaram, Ph.D.
Dr. Nachiappan Chidambaram, Ph.D.
Senior Vice President - Research and Development
Senior Vice President - Research and Development
4.41K
+11.54%
Ms. Krista Fogarty
Ms. Krista Fogarty
Principal Accounting Officer, Corporate Controller
Principal Accounting Officer, Corporate Controller
1.07K
+44.84%
Dr. Richard Dana Ono, Ph.D.
Dr. Richard Dana Ono, Ph.D.
Independent Director
Independent Director
831.00
--
Mr. Jeffrey A. (Jeff) Fink
Mr. Jeffrey A. (Jeff) Fink
Independent Director
Independent Director
386.00
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
4.00%
Patel (Mahesh V)
1.96%
BlackRock Institutional Trust Company, N.A.
1.61%
Geode Capital Management, L.L.C.
1.10%
Susquehanna International Group, LLP
0.84%
Other
90.49%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
4.00%
Patel (Mahesh V)
1.96%
BlackRock Institutional Trust Company, N.A.
1.61%
Geode Capital Management, L.L.C.
1.10%
Susquehanna International Group, LLP
0.84%
Other
90.49%
Shareholder Types
Shareholders
Proportion
Investment Advisor
6.76%
Individual Investor
2.84%
Investment Advisor/Hedge Fund
1.89%
Hedge Fund
0.93%
Other
87.58%
Institutional Shareholding
Updated: Sun, Oct 5
Updated: Sun, Oct 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
32
528.39K
9.52%
-40.19K
2025Q2
44
680.47K
12.56%
-41.55K
2025Q1
65
678.55K
12.68%
-110.89K
2024Q4
72
645.33K
12.07%
-219.30K
2024Q3
75
703.77K
13.16%
-136.61K
2024Q2
79
690.86K
12.92%
-132.01K
2024Q1
82
639.82K
12.02%
-214.82K
2023Q4
86
649.80K
12.29%
-222.39K
2023Q3
91
667.07K
12.61%
-176.35K
2023Q2
93
641.50K
12.32%
-239.33K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
224.88K
4.15%
-1.40K
-0.62%
Jun 30, 2025
Patel (Mahesh V)
109.05K
2.01%
+1.63K
+1.52%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
89.27K
1.65%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
61.08K
1.13%
+2.24K
+3.81%
Jun 30, 2025
Susquehanna International Group, LLP
46.02K
0.85%
+7.04K
+18.06%
Jun 30, 2025
Higuchi (John W)
40.80K
0.75%
--
--
Mar 31, 2025
Renaissance Technologies LLC
34.80K
0.64%
-2.71K
-7.23%
Jun 30, 2025
State Street Investment Management (US)
18.63K
0.34%
--
--
Jun 30, 2025
Northern Trust Investments, Inc.
13.16K
0.24%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
May 11, 2023
Merger
17→1
May 11, 2023
Merger
17→1
May 11, 2023
Merger
17→1
May 11, 2023
Merger
17→1
Date
Type
Ratio
May 11, 2023
Merger
17→1
May 11, 2023
Merger
17→1
May 11, 2023
Merger
17→1
May 11, 2023
Merger
17→1
FAQs
Who are the top five shareholders of Lipocine Inc?
The top five shareholders of Lipocine Inc are:
The Vanguard Group, Inc. holds 224.88K shares, accounting for 4.15% of the total shares.
Patel (Mahesh V) holds 109.05K shares, accounting for 2.01% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 89.27K shares, accounting for 1.65% of the total shares.
Geode Capital Management, L.L.C. holds 61.08K shares, accounting for 1.13% of the total shares.
Susquehanna International Group, LLP holds 46.02K shares, accounting for 0.85% of the total shares.
The Vanguard Group, Inc. holds 224.88K shares, accounting for 4.15% of the total shares.
Patel (Mahesh V) holds 109.05K shares, accounting for 2.01% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 89.27K shares, accounting for 1.65% of the total shares.
Geode Capital Management, L.L.C. holds 61.08K shares, accounting for 1.13% of the total shares.
Susquehanna International Group, LLP holds 46.02K shares, accounting for 0.85% of the total shares.
What are the top three shareholder types of Lipocine Inc?
The top three shareholder types of Lipocine Inc are:
The Vanguard Group, Inc.
Patel (Mahesh V)
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
Patel (Mahesh V)
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Lipocine Inc (LPCN)?
As of 2025Q3, 32 institutions hold shares of Lipocine Inc, with a combined market value of approximately 528.39K, accounting for 9.52% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -3.04%.
What is the biggest source of revenue for Lipocine Inc?
In --, the -- business generated the highest revenue for Lipocine Inc, amounting to -- and accounting for --% of total revenue.
